|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SNHG19 |
Gene summary for SNHG19 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SNHG19 | Gene ID | 100507303 |
| Gene name | small nucleolar RNA host gene 19 | |
| Gene Alias | SNORD60HG | |
| Cytomap | 16p13.3 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 100507303 | SNHG19 | HCC2_Meng | Human | Liver | HCC | 1.10e-12 | -1.78e-01 | 0.0107 |
| 100507303 | SNHG19 | cirrhotic1 | Human | Liver | Cirrhotic | 2.51e-07 | 2.30e-01 | 0.0202 |
| 100507303 | SNHG19 | cirrhotic2 | Human | Liver | Cirrhotic | 2.56e-05 | 2.17e-01 | 0.0201 |
| 100507303 | SNHG19 | cirrhotic3 | Human | Liver | Cirrhotic | 3.86e-10 | 1.74e-01 | 0.0215 |
| 100507303 | SNHG19 | Pt13.a | Human | Liver | HCC | 9.48e-12 | -2.88e-01 | 0.021 |
| 100507303 | SNHG19 | Pt13.b | Human | Liver | HCC | 9.95e-05 | -2.88e-01 | 0.0251 |
| 100507303 | SNHG19 | Pt13.c | Human | Liver | HCC | 2.57e-02 | -2.88e-01 | 0.0076 |
| 100507303 | SNHG19 | Pt14.d | Human | Liver | HCC | 1.01e-10 | -2.88e-01 | 0.0143 |
| 100507303 | SNHG19 | S027 | Human | Liver | HCC | 7.25e-03 | 5.63e-01 | 0.2446 |
| 100507303 | SNHG19 | S028 | Human | Liver | HCC | 2.04e-10 | 1.20e+00 | 0.2503 |
| 100507303 | SNHG19 | S029 | Human | Liver | HCC | 9.34e-03 | 6.44e-01 | 0.2581 |
| 100507303 | SNHG19 | C04 | Human | Oral cavity | OSCC | 1.89e-04 | 4.36e-01 | 0.2633 |
| 100507303 | SNHG19 | C21 | Human | Oral cavity | OSCC | 2.33e-03 | 4.84e-01 | 0.2678 |
| 100507303 | SNHG19 | C30 | Human | Oral cavity | OSCC | 3.44e-10 | 7.67e-01 | 0.3055 |
| 100507303 | SNHG19 | C38 | Human | Oral cavity | OSCC | 1.57e-04 | 7.52e-01 | 0.172 |
| 100507303 | SNHG19 | C43 | Human | Oral cavity | OSCC | 1.01e-03 | 1.62e-01 | 0.1704 |
| 100507303 | SNHG19 | C46 | Human | Oral cavity | OSCC | 7.63e-03 | 2.53e-01 | 0.1673 |
| 100507303 | SNHG19 | C51 | Human | Oral cavity | OSCC | 1.39e-08 | 9.12e-01 | 0.2674 |
| 100507303 | SNHG19 | C07 | Human | Oral cavity | OSCC | 4.95e-02 | 9.49e-01 | 0.2491 |
| 100507303 | SNHG19 | C08 | Human | Oral cavity | OSCC | 1.05e-34 | 8.39e-01 | 0.1919 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |